SCHEMBL279666

SCHEMBL279666

Cc1sc(C(=O)CN2CCC(N)C2)cc1[N+](=O)[O-]

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 5/20 0.34
KDM1A O60341 1/20 0.34
RECQL P46063 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HRH2 P25021 1/20 0.33
HRH1 P35367 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279886 0.74 ALDH1A1 (0.42) POLBALDH1A1RECQLLMNAL3MBTL1
SCHEMBL16863713 0.72 GSK3B (0.40) POLBMAPK1ALDH1A1RECQLLMNA
SCHEMBL15577326 0.68 ALDH1A1 (0.40) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL18019404 0.67 LMNA (0.39) POLBALDH1A1LMNAMAPTL3MBTL1
SCHEMBL1242736 0.67 DAO (0.55) ALDH1A1LMNAMAPTL3MBTL1MEN1
SCHEMBL10252646 0.67 USP47 (0.54) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL426359 0.66 USP10 (0.51) POLBMAPK1ALDH1A1LMNAMAPT
SCHEMBL17977297 0.64 USP10 (0.58) POLBMAPK1ALDH1A1LMNAMAPT
SCHEMBL12226501 0.63 HRH2 (0.44) POLBHRH2HRH1
SCHEMBL12226499 0.63 HRH2 (0.44) POLBHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL POLB 4352/4885MAPK1 474/4885ALDH1A1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.